Abstract: This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology. Exposure of test subjects to the herbicide paraquat (PQ) increases the risk for developing Parkinson's disease. The data in this disclosure show that PQ induces a senescence arrest and SASP in astrocytes, in culture and in vivo in mice, and senescent cell markers were present in astrocytes in midbrain tissue from PD patients. In a transgenic mouse model, senescent cell ablation protected against PQ-induced PD-like neuropathology. Removal of senescent cells from affected sites using small molecule agents that specifically target senescent cells can help prevent or ameliorate signs and symptoms of the disease.

Abstract: A method and system for purification of helium and CO2 from a stream containing at least Helium, CO2, nitrogen or methane uses a combination of cryogenic, membrane and adsorption technologies.

Abstract: An electrical connector assembly includes a first connector member, a second connector member configured for connection with the first connector member, a first insulator disposed at least partially in the first connector member and/or the second connector member, a second insulator disposed at least partially in the first connector member and/or the second connector member, and a circuit board configured to be disposed at least partially between the first insulator and the second insulator in a connected configuration of the electrical connector assembly. The circuit board may include an electrical characteristic sensor and/or a temperature sensor.

Abstract: A sun visor comprises a sun visor body (2) and a vanity mirror assembly (1) comprising a vanity mirror (11) mounted on a support (12). The sun visor comprises a first set of clips (31, 32) configured for snap-fit connection of the vanity mirror assembly (1) onto the sun visor body (2) so that the vanity mirror assembly (1) is held firmly against the sun visor body (2) by the first set of clips, and a second set of clips (41, 42; 51, 52) configured for snap-fit connection of the vanity mirror assembly (1) onto the sun visor body (2) allowing for movement of the vanity mirror assembly (1) in relation to the sun visor body (2). If the snap-fit connection by the first set of clips fails after an impact, the vanity mirror assembly may remain attached to the sun visor body by the second set of clips.

Abstract: An assembly for assembling optical fiber with at least two pairs of MPO contacts. The optical contacts being of the multifiber push-on type. The assembly includes a socket including MPO contacts cooperating with a plug. The plug includes, through axial openings configured to receive the MPO contacts, a first positive-location element positioned in each axial opening of the plug and a second positive-location element positioned on each corresponding MPO contact. A holding element configured to hold the MPO contacts in the plug. The plug shape cooperates with the shape of the socket to ensure coupling thereof. The socket includes locking elements to lock the MPO contacts. Each MPO contact of the plug is locked with the corresponding MPO contact in the socket.

Abstract: Disclosed herein is a method of use of colored dye in ophthalmic surgery. In one embodiment the colored dye is fluorescent. In another embodiment the fluorescent dye is combined with viscoelastic gel for anterior segment eye surgery.

Abstract: An assembly for assembling optical fiber with at least two pairs of MPO contacts. The optical contacts being of the multifiber push-on type. The assembly includes a socket including MPO contacts cooperating with a plug. The plug includes, through axial openings configured to receive the MPO contacts, a first positive-location element positioned in each axial opening of the plug and a second positive-location element positioned on each corresponding MPO contact. A holding element configured to hold the MPO contacts in the plug. The plug shape cooperates with the shape of the socket to ensure coupling thereof. The socket includes locking elements to lock the MPO contacts. Each MPO contact of the plug is locked with the corresponding MPO contact in the socket.

Abstract: In a multi-user, collaborative environment, an operating system state change can occur by passing a stylus pen from one user to another. Upon detecting a change of the active user, a state machine transition can result in a change in a user experience. In one example, a change in the user experience includes a change in user interface (UI) functionality. Some examples include changing color of the digital ink being displayed, changing a handwriting pattern, and automatically switching a view displayed on the user interface. The switched view can be switching from a single-user model to a multi-user model. In another example, a state machine transition can result in establishing connections between devices (e.g., phones or laptops) associated with the users that used the pen.

Abstract: A sun visor comprises a sun visor body (2) and a vanity mirror assembly (1) comprising a vanity mirror (11) mounted on a support (12). The sun visor comprises a first set of clips (31, 32) configured for snap-fit connection of the vanity mirror assembly (1) onto the sun visor body (2) so that the vanity mirror assembly (1) is held firmly against the sun visor body (2) by the first set of clips, and a second set of clips (41, 42; 51, 52) configured for snap-fit connection of the vanity mirror assembly (1) onto the sun visor body (2) allowing for movement of the vanity mirror assembly (1) in relation to the sun visor body (2). If the snap-fit connection by the first set of clips fails after an impact, the vanity mirror assembly may remain attached to the sun visor body by the second set of clips.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract: A technique is described herein for decoupling the playback of media content streams that compose a media item. In one implementation, the technique involves: in a synchronized state, presenting a stream of first media content (such as audio content) in synchronization with a stream of second media content (such as video content); detecting a desynchronization event; in response to the desynchronization event, transitioning from the synchronized state to a desynchronized state by changing (e.g., slowing) a rate at which the stream of second media content is presented, relative to the stream of first media content; detecting a resynchronization-initiation event; and, in response to the resynchronization-initiation event, returning to the synchronized state by providing a compressed presentation of the stream of second media content. The technique further involves presenting the stream of first media content at a given non-zero rate while in the desynchronized state.

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.